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Abstract
Background: The unique metabolism of tumors was described many years ago by Otto Warburg, who identified tumor cells
with increased glycolysis and decreased mitochondrial activity. However, ‘‘aerobic glycolysis’’ generates fewer ATP per
glucose molecule than mitochondrial oxidative phosphorylation, so in terms of energy production, it is unclear how
increasing a less efficient process provides tumors with a growth advantage.
Methods/Findings: We carried out a screen for loss of genetic elements in pancreatic tumor cells that accelerated their
growth as tumors, and identified mitochondrial ribosomal protein L28 (MRPL28). Knockdown of MRPL28 in these cells
decreased mitochondrial activity, and increased glycolysis, but paradoxically, decreased cellular growth in vitro. Following
Warburg’s observations, this mutation causes decreased mitochondrial function, compensatory increase in glycolysis and
accelerated growth in vivo. Likewise, knockdown of either mitochondrial ribosomal protein L12 (MRPL12) or cytochrome
oxidase had a similar effect. Conversely, expression of the mitochondrial uncoupling protein 1 (UCP1) increased oxygen
consumption and decreased tumor growth. Finally, treatment of tumor bearing animals with dichloroacetate (DCA)
increased pyruvate consumption in the mitochondria, increased total oxygen consumption, increased tumor hypoxia and
slowed tumor growth.
Conclusions: We interpret these findings to show that non-oncogenic genetic changes that alter mitochondrial metabolism
can regulate tumor growth through modulation of the consumption of oxygen, which appears to be a rate limiting
substrate for tumor proliferation.
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Introduction
Otto Warburg won the Nobel Prize for physiology or medicine
in 1931, and we are still working to understand the significance of
his discoveries. His work on oxidation and reduction and energy
production is essential for our current understanding of interme-
diate metabolism. Using his newly developed techniques, he
characterized the energy production within solid tumors and
compared it to that in normal tissue [1]. He found that normal
tissues used mitochondrial oxidation to account for 90% of ATP
production with glycolysis accounting for 10%. However, tumors
used less of the highly efficient oxidative phosphorylation,
producing 50% of the ATP from oxidation and 50% from
glycolysis. This shift was thought to occur even though there was
sufficient oxygen to support mitochondrial function and is called
‘‘aerobic glycolysis’’[1]. Although Warburg incorrectly attributed
the cancer phenotype to this metabolic shift, it is difficult to explain
the growth advantage that tumor cells gain by increasing glycolysis
at the expense of oxidative phosphorylation [2]. Glycolysis
produces only two ATP per glucose molecule, along with 2
NADH and 2 molecules of pyruvate. Without mitochondria to
consume the pyruvate, it is converted to lactate and released into
the extracellular space. The conversion of pyruvate to lactate
maintains the redox balance within the cell by regenerating
NAD+, but wastes this energy rich molecule.
Genetic analysis of tumors has since identified oncogenic changes
that have been shown to contribute to the altered tumor metabolism.
Activation of oncogenes such as AKT [3] and myc [4,5] have been
shown to increase glycolysis and glutaminolysis, while loss of tumor
suppressors TP53 [6] or VHL [7] can also shift energy production
away from the mitochondria to a more glycolytic equilibrium. VHL
has been especially informative due to its ability to directly regulate
the hypoxia-inducible transcription factor 1a (HIF1a)[ 8 ] .H I F 1 a is
proteolytically regulated by pVHL primarily by ambient oxygen
concentrations. Low levels of oxygen (or hypoxia) cause the protein to
be stabilized and becomeactivein transcribing genesthought to allow
the cell or tissue to adapt to the hypoxia. Recent work has shown that
not only does HIF1 actively increase glycolysis [9] but it decreases
mitochondrial function [10,11,12] in order to metabolically reduce
the demand of the tissue for oxygen.
In addition to the oncogenic and epigenetic changes within the
tumor that can alter mitochondrial function, tumor mutations
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mitochondrial enzymes. These mutations have been identified in
tumors such as head and neck [13], prostate [14], ovary [15], and
liver [16]. However, it is difficult to determine the role of these
mutations during tumorigenesis, partly because mitochondrial
mutations accumulate naturally during aging [17]. Phenotypic
analysis of cells harboring these mutations showed increased
growth rates in vivo [13,14], and in vitro as well [13]. Both of these
reports attributed the growth differences to a decrease in
mitochonrially produced reactive oxygen species (ROS) when
cells were grown in normoxia. Neither group investigated their
cells in hypoxia or other microenvironmental conditions found in
the tumor. One suggestion that the tumor microenvironment may
be important in understanding the biology of these mutations
comes from Mithani et al who showed that these mutations are
late events during tumor formation [18]. We interpret this late
accumulation of mitochondrial mutations to mean that they
provide a growth advantage at the stage of a macroscopic tumor,
where microenvironmental stresses exist that can in turn regulate
cellular growth.
In addition to mitochondrial DNA mutations, there have
recently been tumor mutations identified in the enzymes of the
TCA cycle. Through genetic studies, fumarate hydrolase and
succinate dehydrogenase have been shown to be tumor suppres-
sors [19,20]. The mechanism by which they can suppress
tumorgenicity has yet to be fully determined, but it has been
shown that these mutations cause a buildup of TCA intermediates
that can lead to stabilization of the HIF1 transcription factor [21].
This condition, termed pseudohypoxia, can increase aggressive-
ness of tumors through the induction of HIF1 target genes such as
VEGF or lysl oxidase. Recently, an unbiased tumor sequencing
project found another related enzyme, isocitrate dehydrogenase,
mutated at high frequency in glioblastomas [22]. Although this is
the cytoplasmic form of the enzyme, it is closely related to the
mitochondrial form, and the physiologic significance of this
mutation is not yet determined.
Poorly formed tumor blood vessels cause a bottleneck that limits
oxygen supply to the growing tumor [23,24]. Oxygen consump-
tion within the tumor causes an imbalance with delivery resulting
in hypoxia and its sequella [25]. Hypoxia has been shown to have
many effects on tumor cells, the severity of the response is
dependent on the level of oxygen deprivation [26,27]. With
respect to tumor growth characteristics, moderate hypoxia causes
a slowing of tumor cell proliferation, while severe hypoxia causes
outright cell death [27,28]. These effects can be seen in vivo as
well as modeled in vitro. Reducing hypoxia by decreasing oxygen
consumption may be the most effective way to bring supply and
demand back in balance and increase tumor growth [25].
Mitochondrial function is responsible for the majority of oxygen
consumption within the cell, accounting for 70–90% of total
oxygen consumption. Reducing mitochondrial function can
therefore have a major effect upon total oxygen utilization.
However, there are only two ways that a cell can generate energy,
so a reduction in mitochondrial oxygen consumption must result
in a compensatory increase in glycolysis.
In this work, we describe a novel unbiased screen for genetic loss
that increased tumor cell growth in vivo. The most dramatic target
identified was in mitochondrial ribosomal protein L28, and its
knockdown resulted in a slower growth in vitro, but paradoxically,
an accelerated growth in vivo. One of the effects of the knockdown
is to change the cellular metabolism to more closely match the
Warburg observations. Some of the differences in growth can be
modeled by altering oxygen availability in vitro. However, these
findings emphasize how the Warburg effect must be studied in the
context of the tumor microenvironment where nutrient supply is
limited by blood supply, unlike the growth conditions in vitro.
Results
An unbiased ShRNA screen identified genes whose knockdown
increased cell growth in vivo. Miapaca2 pancreatic cancer cells
were infected with a lentivirus library containing ShRNA hairpins
targeting 8600 open reading frames with 5 fold redundancy [29].
The infected cells were selected for puromycin resistance and then
either injected into the flank of a nude mouse, or placed in a dish
for growth in an incubator. After one week and four weeks samples
were harvested and the enrichment of each ShRNA determined.
The genes that showed the greatest increase in the in vivo samples
when compared to the in vitro samples are listed in figure S1. At
the top of the list is the mitochondrial ribosomal protein L28
(MRPL28). This is a nuclearly encoded protein that is required for
the correct function of the mitochondrial ribosome, and synthesis
of the mitochondrially encoded proteins [30].
To confirm that the knockdown of this protein would confer a
growth advantage to cells grown as a tumor, two retroviral
plasmids were constructed that expressed either hairpins 1 or 2
from table 1. Virus was made and used to infect both SU86 and
Miapaca2 pancreatic cancer cells. Knockdown was determined by
Western blot and found to be approximately 50% for construct 1
and .90% for construct 2 when compared to cells infected with a
scrambled sequence hairpin (figure 1a). These cells were then
injected into the flank of a nude mouse, and the rate of tumor
growth determined by measuring the volume with calipers.
Knockdown of MRPL28 in either of these cell lines resulted in
approximately a 2–3 fold increase in tumor growth. Because
MRPL28 is necessary for mitochondrial function, we tested the
knockdown of other proteins essential to mitochondrial function to
determine if this would phenocopy the MRPL28 knockdown. We
found that knockdown of either mitochondrial ribosomal protein
L12 or cytochrome oxidase subunit 4 resulted in a similar increase
in tumor growth in vivo (figure 1b and 1c). We also found that
expression of a truncated MRPL28 could increase tumor growth
as well. (figure S2) This fragment appears to have dominant
interfering activity in our growth and functional assays (figure S2).
To determine the role of MRPL28 knockdown on mitochon-
drial function, we analyzed the knockdown cells in vitro. We first
used the protein extracts from figure 1 above, and probed for the
expression of a mitochondrial protein that was encoded in the
mitochondrial genome (COXlll), and one that was encoded in the
nuclear genome (HSP60). We found that knockdown of MRPL28
resulted in a commensurate reduction in the mitochondrial
protein, with little effect on the nuclear-encoded protein
(figure 2A), suggesting that the mitochondrial ribosome was
compromised. We examined the knockdown cells for any gross
abnormalities in mitochondrial structure by immunostaining with
anti cytochrome C antibody. Mitochondrial structure and quantity
appeared normal by this assay (figure 2B). We also examined
biochemical parameters of the mitochondria using the functional
stain Rhodamine 123 (Rh123), and the mitochondrial stain Nonyl
acradine orange. Figure 2C shows that the membrane potential
(Rh123 intensity) and the total mitochondrial mass (NAO
intensity) were not changed by the knockdown of MRPL28.
However, when we examined the metabolic parameters of these
cells we found a significant effect of the knockdown. Figure 2E
shows that mitochondrial oxygen consumption is significantly
reduced in the knockdown of MRPL28 in both Su86 and
Miapaca2 cells. We found that the greater the reduction in
MRPL28 expression, the greater the reduction in the mitochon-
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function suggests that these cells must have a compensatory
increase in glycolytic energy production. Analysis of the knock-
down cells for glucose uptake with radiolabelled glucose showed an
increase relative to the control cells (figure 2F). Much of the
increased glucose uptake appears to be used in glycolysis, as these
cells also show an increase in lactate production as well. (Figure 2G)
In order to test the hypothesis that altering oxygen consumption
can alter tumor growth, we generated cells with increased
consumption to test if they showed slower tumor growth. To
accomplish this, we overexpressed the mitochondrial uncoupling
protein 1 (UCP1), which can dissipate the proton gradient across
the inner mitochondrial membrane without generating ATP. The
result is increased oxygen consumption without increased ATP
generation. Figure 3A shows that over 90% of the cells express the
introduced UCP1 protein by immune-fluorescence. These cells
showed a significant level of uncoupling when mitochondrial
function was tested in the presence of oligomycin (figure 3B).
Oligomycin inhibits the F1F0 ATPase and blocks oxygen
consumption in coupled mitochondria. Addition of oligomycin
had little effect on UCP1 overexpressing cells, while it decreased
oxygen consumption in control cells (figure 3B). However, UCP1
expression had little effect on baseline oxygen consumption
(figure 3B and 3C). Because it is known that hypoxia can reduce
mitochondrial function, we tested these cells after treatment with
hypoxia, and found that in this environment that UCP1 expression
resulted in significantly increased oxygen consumption when
compared to control cells (Figure 3C). After determining that these
cells showed increased oxygen consumption, we tested them for
tumor growth, and found that as predicted, they did have
decreased growth in vivo. (Figure 3D).
Working with these cells in the lab, it appeared that the
MRPL28 knockdown (and the MRPL12 and COX1V knockdown
also) cells grew more slowly in vitro. We therefore tested the
growth of MRPL28 knockdown cells for colony formation in
normoxia, and hypoxia, a condition that would be prominent in
vivo, and capable of regulating growth. We found that moderately
severe hypoxia of 0.2% could greatly inhibit the growth of the
control cells infected with the scrambled sequence hairpins.
However, while the MRPL28 cells grew more slowly in normoxia,
they were not inhibited as the parental cells were in hypoxia
(figures 4A and 4B). This slow growth of the knockdown cells in
21% oxygen could be due to the accumulation of toxic oxygen
radical byproducts that are reduced in hypoxia. We tested this
hypothesis by measuring the growth rates of these cells in
normoxia in media that had been supplemented with the
scavenger N-acetyl cysteine. However, protection against ROS
with this drug had no effect on the normoxic growth of the
MRPL28 knockdown cells. (figure 4C).
These knockdown cells therefore seem to have a metabolism
that functions more efficiently in vivo while sacrificing efficient
growth in vitro. We therefore analyzed these metabolic and
growth parameters in the tumors grown from cells with control
and MRPL28 knockdown hairpins. Using the radiotracer 18F
labeled 2-deoxyglucose, we measured glucose uptake in vivo. Even
accounting for the larger size of the tumors, we found that the
Figure 1. Knockdown of MRPL28 in pancreatic tumor cells increases tumor formation. Figure 1A) Left panel is a western blot showing
knockdown of MRPL28 by ShRNA constructs 1 and 2 from figure S1 after infection of SU86cells. Middle panel shows tumor growth of SU86 cells
infected with scrambled ShRNA or ShRNA2. Right panel shows growth of Miapaca2 cells after the infection with the indicated constructs. Figure 1B)
Shows Western blot and increased tumor growth after knockdown of MRPL12 in SU86 tumor cells. Figure 1C) Shows western blot and increased
tumor growth after knockdown of cytochrome oxidase subunit 4 in Su86 tumor cells.
doi:10.1371/journal.pone.0007033.g001
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(figure 5A). We also tested fresh tumor explants for oxygen
consumption differences, and found that the knockdown tumors
had significantly lower oxygen consumption per mg of tumor than
the control tumors (figure S3). Because we had determined that the
rate of oxygen consumption can influence tumor hypoxia [31], we
next measured hypoxia in these tumors by the relative binding of
the marker drug pimonidozole. We found that the MRPL28
knockdown tumors had a significant reduction in the overall
hypoxic fraction within the tumor when compared to sizxe
matched controls (figure 5B). Lastly, we examined the tumors to
determine if the reduced hypoxia had a significant effect on tumor
growth parameters. While we found no difference in the fraction of
tumor cells that were apoptotic (data not shown), we did find an
increase in the fraction of cells that were proliferating as measured
by uptake of the radiotracer 18F fluorothymidine (Figure 5C left
panel and figure S4). To confirm that the 18F thymidine uptake
represented increased proliferation, we also measured proliferation
by staining histologic sections with anti-Ki67 antibody, and
determined a significant increase in the knockdown tumors
(figure 5C right panel).
We next asked if we could phenocopy this genetic characteristic
of increased mitochondrial function and decreased tumor growth
pharmacologically. One drug that has been shown to increase
mitochondrial activity is dichloroacetate (DCA). DCA is a
pyruvate-mimetic that can increase pyruvate dehyrogenase activity
in hypoxic cells by inhibiting pyruvate dehydrogenase kinases [31].
The increase in PDH activity increases oxygen consumption, and
hypoxia, in the hypoxic tumor. Although additional activities of
DCA have been reported [32,33], we treated animals bearing
SU86 tumors with either PBS or 50 mg/kg DCA on a daily
schedule. The tumors in the DCA treated group showed
significantly slower growth than the control tumors (figure 6A).
At the end of the experiment the animals were injected with
pimonidozole and the tumors harvested and stained for pimoni-
dozole uptake. Figure 6B shows that even though the control
tumors were much larger, there was significantly more hypoxia in
the DCA treated tumors (Figure 6B).
Discussion
There are numerous reports of mutations in the mitochondrial
genomes of tumor cells, or in enzymes of the mitochondrial TCA
cycle, suggesting that these alterations are beneficial for tumor
growth. However, these mutations can accumulate with age, and
so it is difficult to show that they have a functional role during
tumorigenesis. Additionally, it is not clear if these mutations have
additional, non-metabolic effects, such as altering apoptotic
sensitivity [34], or interfering with the HIF1 signaling pathway
[13]. Conversely, it is difficult to reduce mitochondrial function
without increasing glycolysis as these are the only two mechanisms
for generating ATP in the cell. This work supports the hypothesis
that it is the mitochondrial activity that is first reduced that causes
the increase in glycolytic activity secondarily. Furthermore, it
provides a functional link between the altered tumor metabolism
described by Warburg and the increased tumor growth in vivo.
Tumor cell metabolism is designed to support the synthesis of a
complete daughter cell each cell cycle. This requires the
coordinated production of the biochemical precursors necessary
for macromolecular synthesis. The metabolic pathways that
generate energy intersect most directly with the pathways
responsible for nucleic acid synthesis (the use of glucose-6-
phosphate in the pentose shunt) and lipid synthesis (acetylCoA
from the mitochondria for 2 carbon lipid extension at fatty acid
Figure 2. Knockdown of MRPL28 results in a dose-dependent
decrease in mitochondrial function. Figure 2A) Western blot of the
extracts from figure 1 probed for mitochondrially encoded COX111 and
nuclearly encoded mitochondrial HSP60. Figure 2B) Micrograph of
control and MRPL28 knockdown SU86 cells stained with anti-
cytochrome C showing no significant alteration in mitochondrial
morphology. Figure 2C) Determination of mitochondrial membrane
potential by staining with Rhodamine123 in control and MRPL28
knockdown Miapaca2 cells showing no difference in either basal or
uncoupled conditions (addition of 1 ug/ml CCCP). Figure 2D) Staining
of total mitochondrial mass with nonyl acradine orange (NAO) in
control and MRPL28 knockdown Miapaca2 tumor cells showing no
difference. Panel 2E) Determination of reduced mitochondrial oxygen
consumption in MRPL28 knockdown SU86 (left panel) and Miapaca2
cells (right panel). Panel 2F) Shows increased
3H-labelled 2-deoxyglu-
cose uptake in the MRPL28 knockdown Miapaca2 tumor cells compared
to the scrambled ShRNA control. Panel 2G) Shows increased lactate
production in the media after 16 hours of growth of MRPL28
knockdown Miapaca2 cells when compared to scrambled ShRNA
control cells.
doi:10.1371/journal.pone.0007033.g002
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molecular synthesis could provide tumor cells with additional
capacity for macromolecular production. Activation of the AKT
oncogene has been shown to alter metabolism and shift the flow of
precursors into molecular synthesis[36]. However, this does not
appear to be the case for the mutations that we report here
because they actually slow the growth of tumor cells in vitro in
normoxia where there is excess glucose and oxygen in the media
[37]. It is only in the hypoxic environment where oxygen is
limiting that the mutations are beneficial to cellular proliferation
(figure 4).
The HIF1 transcription factor has also been shown to influence
the metabolic choices within the tumor cell. This adaptive
response slows oxygen consumption and increases glucose
metabolism during hypoxia [23]. This observation is consistent
with the idea that oxygen can be rate limiting for growth in vivo,
and slowing its consumption contributes to accelerate tumor
proliferation. The HIF1 data has also been interpreted by some to
support a model in which reduced mitochondrial function leads to
reduced generation of toxic oxygen byproducts, or reactive oxygen
species (ROS), and therefore decreases cellular death [10,12]. It is
true that slowing the oxygen flux through the mitochondria will
slow the metabolic production of ROS, but the role of ROS in
killing hypoxic cells is controversial [38,39,40]. Our data suggests
that ROS are not toxic to the cells in either normoxia or hypoxia.
The addition of the radical scavenger N-acetyl cysteine (NAC) to
the media does not protect the mutant cells during growth at 21%
oxygen (figure 4). Additionally, there is not increased death of cells
in the wild type tumors as measured by staining with TUNEL for
apoptosis (data not shown).
The hypothesis that oxygen can be limiting to the growth of
human tumors has been presented. What has been difficult to
generate is a genetic model system that can test this independent of
other activities. In the 1950’s Thomlinson and Gray made the
observation that human tumor cells grew in vivo around blood
vessels but only for a limited distance [41]. This architecture of the
‘‘tumor cord’’ has been shown to be a function of the need for
tumor cells to extract oxygen from the blood vessel. However,
oxygen is consumed as it diffuses through the cells. The diffusion
distance of approximately 100–200 microns is a function of the
Figure 3. Increased mitochondrial oxygen consumption decreases tumor growth. Figure 3A) Immunodetection of stably transfected
uncoupling protein 1 (UCP1) in Miapaca 2 cells. Note nearly 100% transduction. Figure 3B) Uncoupling of mitochondria by expression of UCP1.
Mitochondrial oxygen consumption at baseline and in the presence of 1 ug/ml oligomycin to block the F1F0ATPAse. Note continued oxygen
consumption in the uncoupled cells. Figure 3C) Increased oxygen consumption in UCP1 expressing Miapaca 2 cells exposed to hypoxia. Note similar
oxygen consumption in normoxia. Figure 3D) Slower tumor growth in Miapaca2 cells expressing the UCP1 gene and presumably due to increased
oxygen consumption.
doi:10.1371/journal.pone.0007033.g003
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within the cell [42,43]. This oxygen diffusion limit limits the
proliferation of the tumor cells. However, if the tumor cells are
able to decrease the rate with which they consume oxygen, the
diffusion limit will be increased [44]. Active downregulation of
mitochondrial function by HIF1 can accomplish this reduction in
oxygen consumption similarly to the mutations that we generated.
Pharmacologically blocking this adaptive response with DCA leads
to increased oxygen consumption and reduced tumor growth. The
pancreatic tumor cells seem to be sensitive to this intervention, and
this cell-type sensitivity should be taken into account as clinical
trials progress with this drug [45].
Oxygen is required for non-mitochondrial activities that are
required for growth of tumor cells. This requirement for oxygen
allows tumor cells to grow in hypoxia, but cannot support growth in
a n o x i a .T h i sa n o x i cd e a t hc a nb eo b s e r v e di nv i v oa sw e l la si nv i t r o
[27,46]. As it has been shown in yeast, loss of mitochondrial function
allows slow growth of ‘‘petite’’ colonies on a source of glucose, but will
not support growth in anoxia [47]. Several processes have been
identified that require molecular oxygen as a substrate, such as sterol
synthesis, or oxidative protein folding [48,49]. Neither of these
processes can occur in the total absence of oxygen, but can efficiently
proceed in moderate hypoxia. Furthermore oxidases, hydroxylases,
and histone demethylases all require molecular oxygen as a substrate
[44]. These oxygen-dependent cellular functions are necessary for the
growth of cells within the tumor. This model of how decreased
mitochondrial function provides tumor cells with additional sub-
strates (ie oxygen) for macromolecular synthesis could be considered
an outgrowth of the model in which increased glycolysis provides
tumor cells with increased small molecule intermediates for increased
macromolecular synthesis [35].
Materials and Methods
Cell lines and cell culture
Su86.86 and MiapaCa2 human pancreatic cancer cells were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA). Su86.86 were grown in RPMI1640 supplemented
with sodium pyruvate and Hepes and 10% fetal bovine serum
(FBS), while MiapaCa2 cells were grown in Dulbecco’s Modified
Eagle’s Media (DMEM) supplemented with 10% FBS. For
moderate hypoxia, cell culture dishes were placed into an Invivo2
humidified hypoxia workstation (Ruskinn Technologies, Bridgend,
UK) at the indicated oxygen concentrations.
Plasmids and siRNAs
Full-length human UCP1 cDNA was obtained from the
mammalian gene collection (MGC), through the ATCC, and
was cloned into pBabePuro vector. For knockdown experiments,
the target sequences used were: Complex IV subunit IV,
CACTGAAGGAGAAGGAGAA, MRPL12, CAACGAGCTC-
CTGAAGAAA. MRPL28 shRNA1, TACAAGGAATTTGC-
CATCCCAGAGGA, and shRNA2, GCCAAGTTCAAGAT-
CAAC. For construction of stable knockdown cell lines, the
sequences listed above were cloned into pSIREN-RetroQ vector.
All the knock down cells were selected with 1 mg/ml puromycin
for at least one week and a pool of the infected cells were used for
each of the experiments.
Oxygen consumption measurements and Pimonidozole
staining
Cells were trypsinized and suspended at 6610
6 cells per ml in
DMEM + 10% FBS. Oxygen consumption was measured in a
0.5 ml volume using an Oxytherm electrode unit (Hansatech,
Norfolk, UK). This system employs a Clark-type oxygen electrode
to monitor the dissolved oxygen concentration in a sealed
measurement chamber over time. The data are exported to a
computerized chart recorder (Oxygraph 1.01, Hansatech, Norfolk,
UK), which calculates the rate of oxygen consumption. A small stir
bar maintains the cells in suspension, and a peltier heating block
maintains the temperature at 37uC. Since the electrode consumes
oxygen during measurement, the rate of oxygen drop in 0.5 ml of
DMEM media without cells was established and subtracted from
the total oxygen consumption rates for the cell suspensions.
Pimonidozole staining was performed on animals injected with
60 mg/kg pimonidozole 3 hours prior to sacrifice. Pimonidozole
was detected by immunofluorescence of frozen sections (figure 5)
or by flow cytometry of a single cell suspension (figure 6). Cells
were blocked with PBS containing 0.1% triton and 3% fat free
milk, and detected with FITC-labeled Hypoxyprobe-1 antibody.
Figure 4. Knockdown of MRPL28 results in slower growth of tumor cells in vitro. Figure 4A) Xrystal violet stained colony formation of
control scrambled ShRNA and MRPL28 knockdown Miapaca2 cells grown in normoxia and in o.2% oxygen. Figure 4B) Quantitation of plating
efficiency shown in figure 4A. Note fewer colonies in normoxia in the knockdown cells, and less of a decrease in moderately severe hypoxic
conditions. Figure 4C) Addition of the oxygen radical scavenger NAC does not rescue the growth of the normoxic MRPL28 Miapaca2 knockdown
tumor cells. Growth of scrambled control ShRNA cells (closed symbols) and MRPL28 knockdown cells (open symbols). Cell number is reported for
growth in control media (dark symbols), or media containing 10 mM NAC (light symbols).
doi:10.1371/journal.pone.0007033.g004
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siRNA library screen
The GeneNet
TM Human Druggable Genome siRNA Library
contains 43,800 siRNA templates targeted to 8,500 well-
characterized human genes (System Biosciences, CA). For most
of the target genes, there are five different siRNA sequences. The
library is cloned into the FIV-based pSIF1-H1-Puro shRNA
Expression Vector, which confers resistance to the antibiotic
puromycin. After transducing the cells with pre-packaged VSV-G
pseudotyped virus containing the siRNA library, the MiaPaCa2
cells were selected with puromycine for 5 days. Three million cells
with puromycine resistance were injected into Scid mice. One and
four weeks later, the mice were sacrificed and RNA from tumors
was extracted. The lentiviral inserts—containing the siRNA
templates were recovered by PCR and identified using the
Human Genome Focus GeneChipH Array (Affymetrix, CA).
Figure 5. Metabolic changes cause accelerated growth the MRPL28 knockdown tumors. Figure 5A Glucose uptake by microPET
determination of 18F labeled deoxyglucose. Animals bearing one control scrambled ShRNA tumor and one MRPL28 knockdown SU86 tumor were
injected with 200 uCi FDG; and imaged one hour later. Left panel shows heat map with MRPL28 tumors with increased uptake. Right panel shows
quantitation of FDG uptake is increased independent of tumor size. Figure 5B) Size matched control Scrambled ShRNA SU86 and MRPL28 knockdown
tumor bearing animals were injected with pimonidozole and 3 hours later sacrificed. Tumors were sectioned and stained for pimonidozole binding.
Representative sections are shown in left panel and quantitation of hypoxic fraction shown in right panel. Figure 5C) Tumor proliferation in vivo was
determined by 18F labeled thymidine for cellular proliferation. Animals bearing one control scrambled ShRNA and one MRPL28 knockdown SU86
tumor were injected with 200 uCi of 18F-thymidine and two hours later imaged. The PET signal was marginally increased, so tumor cell proliferation
was confirmed by Ki67 staining of sections taken from the tumors. Right panel reports Ki67 positive cells per high powered field.
doi:10.1371/journal.pone.0007033.g005
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microPET scans were performed on a microPET R4 rodent
model scanner (Concorde Microsystems Inc.). Mice bearing
tumors on the shoulders were injected through tail-vein of
200 mCi of radiotracer (
18F-FDG) under isoflurane anesthesia.
The microPET data acquisition was started 60 min after injection.
The images were reconstructed by a 2-dimensional ordered-
subsets expectation maximum (OSEM) algorithm and no
correction was necessary for attenuation or scatter.
Western blotting
In brief, treated cells were harvested directly in buffer
containing 8 M urea and 15 mM b-mecaptoethanl, protein
concentrations were quantitated, 50–100 mg were electrophoresed
on a reducing Tris-Tricine gel, and electroblotted to PVDF
membrane. Antibodies used were MRPL12 (1:200, Abnova),
MRPL28 (1:200, Genway), HSP60, ATPaseIP, COXIII and
Complex IV subunit IV (1:500, Mitosciences). Primary antibodies
were detected with species-specific secondary antibodies labeled
with peroxidase (Vector labs 1:3000) and visualized with Super-
signal substrate (Pierce) with films.
Immunocytochemistry and fluorescence microscopy
Cells were plated on glass multiwell chamber slides (Nalge
Nunc, Naperville, IL) in DMEM + 10% FBS. For cytochrome c
immunocytochemistry, chamber slides were fixed in 4% parafor-
maldehyde, blocked in PBS Tween milk (0.2% Tween 20, 5%
nonfat dry milk, in PBS) for 1 h. Cytochrome c was visualized
using a mouse monoclonal antibody 1:250 (BD Pharmingen, San
Diego, CA) and an anti-mouse Alexa 488 secondary antibody
1:500 (Molecular Probes).
Metabolite Assays
2-Deoxyglucose uptake assay: 2-[1,2,-3H (N)]-Deoxy-D-glucose
was purchased from PerkinElmer. Cells were plated in six-well
plates and 24 hours later were washed with PBS and fresh media
containing 0.5 mM glucose and 0.5 mCi
3H-2DG were added for
30 min. At the end of the incubation the monolayers were rinsed
three times with cold PBS, lysed with 0.2 M NaOH/0.1% SDS
and radioactivity measured with a liquid scintillation counter.
Protein concentration was measured in parallel series of samples.
Lactate measurement assay: Lactate concentrations in the culture
media were measured using a colorimetric assay kit (SUNY at
Buffalo).
Data analysis
Oxygen consumption experiments were repeated three times in
duplicate, survival was measured three times in triplicate, reporter
assays were repeated two times in quadruplicate. Tumor growth
was determined in two separate experiments with 5 tumors per
group. Error bars represent the SEM.
Supporting Information
Figure S1 Table describing the targeting sequences of the
ShRNA hairpins that scored the most consistent enrichment when
comparing 1 and 4 weeks in vivo to the same time in vitro.
Found at: doi:10.1371/journal.pone.0007033.s001 (0.79 MB TIF)
Figure S2 Growth characteristics of the truncated MRPL28-
FLAG expressing Su86 cells grown in vivo (left panel). Oxygen
consumption data from the same overexpressing cells (Right
panel)
Found at: doi:10.1371/journal.pone.0007033.s002 (0.26 MB
TIF)
Figure S3 Analysis of the MRPL12 knockdown tumors ex vivo.
Tumors were explanted and a portion used to determine
knockdown efficiency by Western Blot (left panel) and a portion
used to measure oxygen consumption (tight panel). Minced tumor
sections were weighed and placed in the oxygen electrode to
determine consumption per mg of tumor.
Found at: doi:10.1371/journal.pone.0007033.s003 (0.31 MB TIF)
Figure S4 Quantitation of the mean FLT signal from the
Miapaca2 control tumors and MRPL28 knockdown tumors
imaged in figure 5c.
Found at: doi:10.1371/journal.pone.0007033.s004 (0.14 MB TIF)
Figure 6. Pharmacologic increase in oxygen consumption results in slower tumor growth. Figure 6A) SU86 tumors were grown in nude
mice and when tumors reached 100–200 mm3, animals were divided into control (PBS) and treated (50 mg/kg DCA IP) groups. Animals were treated
daily from day 2 to 16 and tumor volumes measured as indicated. Figure 6B) At day 21 animals were injected with DCA, one hour later by
Pimonidozole and 3 hours later sacrifieced. Tumors were explanted and a single cell suspension generated that was stained with FITC-labelled anti-
pimonidozole antibody. Cells were analyzed by FACS and the fraction staining .200 (AUs) is indicated.
doi:10.1371/journal.pone.0007033.g006
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